Suzhou Fengbei Biotech Stock Co., Ltd. Class A

Suzhou Fengbei Biotech Stock Co., Ltd. Class A

SSSE:603334
24.88
CNY
-0.14
(-0.56%)
0.93EPS
34.26P/E
4.56BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A carries a market capitalization of 4.56B, placing it among publicly traded companies globally. Its enterprise value stands at 4.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.56B
Enterprise Value4.13B

Share Statistics

As of September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A has 143.50M shares outstanding.

Shares Outstanding143.50M

Valuation Ratios

As of September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 34.26. The price-to-sales ratio is 1.04, and the price-to-book ratio stands at 2.59.

PE Ratio34.26
PS Ratio1.04
PB Ratio2.59
P/TBV Ratio2.77

Enterprise Valuation

As of September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A trades at an EV/EBITDA multiple of 27.08 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.08 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.13B versus a market cap of 4.56B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.94
EV / EBITDA27.08
EV / EBIT27.08

Financial Position

As of September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A maintains a current ratio of 3.62, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.95, indicating elevated leverage, while an interest coverage ratio of 30.83 demonstrates strong ability to service its debt obligations.

Current Ratio3.62
Quick Ratio1.53
Debt / Equity14.95
Debt / EBITDA1.73
Interest Coverage30.83

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 11.15M in revenue per employee across its workforce of 395.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee11.15M
Employee Count395.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A recorded 16.89M in income tax expense. That works out to an effective tax rate of 11.21, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 150.69M, leaving 133.76M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax16.89M
Effective Tax Rate11.21

Stock Price Statistics

CNY

As of the close on November 17, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A's stock has declined approximately 48.11% over the past 52 weeks. The 50-day moving average sits at 29.76, while the 200-day moving average is 40.62.

52-Week Price Change-48.11%
50-Day Moving Average29.76
200-Day Moving Average40.62

Income Statement

CNY

Over the twelve months ended September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A generated 4.40B in revenue and converted that into 133.76M in net income, yielding earnings per share of 0.93. EBITDA reached 152.42M, while operating income came in at 175.79M.

Revenue4.40B
Gross Profit280.75M
Operating Income175.79M
Pretax Income150.69M
Net Income133.76M
EBITDA152.42M
EBIT152.42M
Earnings Per Share (EPS)0.93

Balance Sheet

CNY

As of September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A holds 704.79M in cash and equivalents against 263.76M in total debt, resulting in a net debt position of 110,297.39. Total book value stands at 1.76B, with working capital of 1.21B providing operational flexibility.

Cash & Cash Equivalents704.79M
Total Debt263.76M
Net Debt110,297.39
Equity (Book Value)1.76B
Book Value Per Share12.26
Working Capital1.21B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-26.86M

Margins

Over the twelve months ended September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A posted a gross margin of 6.38, reflecting its pricing power and cost economics. The operating margin of 3.99 and net profit margin of 3.04 provide insight into operational efficiency.

Gross Margin6.38
Operating Margin3.99
Pretax Margin3.42
Profit Margin3.04
EBITDA Margin3.46

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A paid dividends of 0.38 per share. The dividend payout ratio of 41.12 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -13.59, meaning Suzhou Fengbei Biotech Stock Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.38
Payout Ratio41.12
Shareholder Yield-13.59

Scores

As of September 30, 2026, Suzhou Fengbei Biotech Stock Co., Ltd. Class A has an Altman Z-Score of 8.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.71